Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway.
Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway.
Rui Feng,Tong Meng,5 Authors,Cheng Yang
2024 · DOI: 10.1016/j.molimm.2024.03.002
Molecular Immunology · 4 Citations
TLDR
It was found that isoliquiritigenin treatment could reduce the secretion and invasion of pro-inflammatory cytokines in prostate tissue and reduced prostate inflammation and pelvic pain in EAP mice.